EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Oncternal Therapeutics's Enterprise Value is $-9.40 Mil.
Oncternal Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-32.16 Mil. Therefore, Oncternal Therapeutics's EV-to-FCF for today is 0.29.
The historical rank and industry rank for Oncternal Therapeutics's EV-to-FCF or its related term are showing as below:
ONCT'
s EV-to-FCF Range Over the Past 10 Years
Min: -10.9 Med: 1.4 Max: 1.85
Current: 0.29
During the past 13 years, the highest EV-to-FCF of Oncternal Therapeutics was 1.85. The lowest was -10.90. And the median was 1.40.
ONCT's EV-to-FCF is ranked better than 83.76% of 394
companies
in the Biotechnology industry
Industry Median: 4.23
vs ONCT: 0.29
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Oncternal Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Oncternal Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncternal Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncternal Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Oncternal Therapeutics's EV-to-FCF falls into.
Oncternal Therapeutics's current Enterprise Value is $-9.40 Mil.
Oncternal Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-32.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Oncternal Therapeutics's PE Ratio for today is calculated as:
Oncternal Therapeutics's share price for today is $8.29.
Oncternal Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.430.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Oncternal Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Oncternal Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Oncternal Therapeutics (Oncternal Therapeutics) Business Description
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ONCT has been successfully added to your 